去纤维钠在中国上市时间

Time on the market in China: Defibrotide sodium (defiteli) is the first drug in the United States to treat severe hepatic venous occlusion. It was approved for marketing in 2016. Currently, defibrotide sodium is not on the market in China, and the approval of imported drugs for domestic marketing is a relatively complicated process, and the specific launch time is unknown.

Defibrinated sodium has anti-thrombotic, fibrinolytic, anti-ischemic and anti-infectious effects in vivo and in vitro. Not only for adults, it also plays an important role in the treatment of pediatric patients.

The effect of defibrotide was studied in the treatment of HVOD in children with a median age of 8.2 years (range, 0.2-20 years). The results showed that the complete response (CR) rate was 76%, and the overall survival (OS) rate 100 days after transplantation was 64%. Among them, the CR rate of 22 SHVOD patients was 50%, and the OS rate 100 days after transplantation was 36%.

The international price of defibrotide sodium (defibrotide) is around $22,000. Although it has not yet been launched in my country, it may be available in some pharmacies in Hong Kong. Patients can also choose to purchase defibrinated sodium in countries or regions such as the United States and European Union countries that are already on the market. However, whether they are going to Hong Kong or buying abroad, the long journey is not convenient for most patients. Especially when going abroad has to face the problem of language barrier, it is not the best choice.

For domestic patients who are inconvenient to travel far, it is most appropriate to choose a professional overseas medical consulting service company. Medical Travel is a company specializing in transnational medical consulting. The company has long-term cooperation with many overseas hospitals and pharmacies, and can help patients buy genuine products (defibrotide) from formal channels.

Recommended related hot articles: /newsDetail/71764.html